Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Short-term Investments (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Short-term Investments for 13 consecutive years, with $5.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Short-term Investments rose 2.0% to $5.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.1 million, a 2.0% increase, with the full-year FY2025 number at $5.1 million, up 2.0% from a year prior.
  • Short-term Investments was $5.1 million for Q4 2025 at Madrigal Pharmaceuticals, down from $814.1 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $814.1 million in Q3 2025 to a low of $5.0 million in Q4 2024.
  • A 5-year average of $313.8 million and a median of $234.1 million in 2021 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: crashed 88.37% in 2022, then skyrocketed 349.77% in 2024.
  • Madrigal Pharmaceuticals' Short-term Investments stood at $234.1 million in 2021, then plummeted by 88.37% to $27.2 million in 2022, then skyrocketed by 525.51% to $170.3 million in 2023, then crashed by 97.06% to $5.0 million in 2024, then grew by 2.0% to $5.1 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Short-term Investments are $5.1 million (Q4 2025), $814.1 million (Q3 2025), and $610.8 million (Q2 2025).